Utility of point of care viscoelastic haemostatic assays for trauma patients in the emergency department.

"This is the first study to systematically compare multiple next generation VET and platelet aggregation systems in both healthy and septic patients under controlled PTS transport conditions. It is hypothesized that PTS-induced acceleration may alter test results. Identifying a critical threshold could ensure safe, rapid blood transport without compromising diagnostic quality, potentially reducing personnel needs and expediting therapy initiation."

TEG® 6s-Guided Algorithm for Optimizing Patient Blood Management in Cardiovascular Surgery: Systematic Literature Review and Expert Opinion.

Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.

The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.

Amplitude at 10 min in thromboelastography predicts maximum amplitude: a single-center observational study.

New interest in fibrinogen as an ischemic risk factor.

While new cartridge-based VHA devices simplify point-of-care testing, their clinical value is not yet fully established. Current research highlights a lack of interchangeability between devices and a shortage of data linking them to patient outcomes or comparing them to rapid conventional assays. Consequently, despite their technical promise, robust randomized clinical trials are still required to prove their utility in critical care settings.

Viscoelastic testing (VET) has revolutionized modern coagulation management by offering rapid, real-time insights into the entire hemostatic process. By enabling precise, data-driven transfusion algorithms at the point of care, VET-guided strategies significantly improve patient blood management and clinical outcomes in high-stakes environments like trauma and cardiac surgery.

Perioperative changes in coagulation and platelet contribution to clot strength after transcatheter aortic valve implantation: A study using thromboelastography and conventional markers.

"Both TEG 5000-FLEV and TEG 6s-CFF correlated moderately with Clauss fibrinogen but decreased in correlation in both hyperfibrinogenemia and hypofibrinogenemia. Thus, we caution relying on TEG 5000 or TEG 6s to be the only laboratory measurement to guide fibrinogen replacement when resuscitating trauma patients at risk for TIC and TEG 5000-FLEV for assessing fibrinogen in patients with ESRD at risk for thrombotic events."

Comparison between the Fibrinogen Clauss Assay and the TEG6S Citrated Functional Fibrinogen in Cardiac Surgery.

"Upregulated thrombin generation parameters after PCC spiking were not displayed by CT, ACT [ROTEM® Delta, ClotPro®, TEG®6s, and Quantra®], or standard tests. Our results do not support treatment algorithms using prolonged CT or ACT as a trigger for administration of PCC to augment thrombin generation."

VHA-guided MHP showed marked variation with inconsistent transfusion thresholds [ROTEM® Sigma and TEG 6 s platforms within major haemorrhage protocols]. For similar clot kinetics, dosing of blood products and haemostatic agents differed, particularly PCC. Patients with the same coagulopathy may receive different treatment across hospitals. Centralised standardisation could improve PBM consistency.

Agreement between the thromboelastography reaction time parameter using fresh and citrated whole blood during extracorporeal membrane oxygenation with Teg®5000 and Teg®6s.

"The present study revealed acceptable agreement between four different assays measuring functional fibrinogen, with current- and previous-generation ROTEM® machines (Sigma, Delta) performing similarly measuring functional fibrinogen via FIBTEM assay. This suggests that haemostatic resuscitation algorithms designed for the ROTEM® Delta can be applied to the ROTEM® Sigma to guide fibrinogen replacement."

Diagnostic Agreement Between TEG5000 and TEG6S in the Assessment of Hemostasis in Pediatric Cardiac Surgery: A Prospective Non-inferiority Study.

Sensitivity and specificity of thromboelastography for hyperfibrinolysis: Comparison of TEG 5000 and TEG 6S CK LY30 systems.

Comparison between the Rotational Thromboelastometry (ROTEM) Delta device against the Cartridge-based Thromboelastography 6s and Quantra in a healthy third trimester pregnant cohort.

Viscoelastic coagulation testing in Neonatal Intensive Care Units: advantages and pitfalls in clinical practice.

Modern cartridge-based VET - specifically the TEG 6s, HemoSonics Quantra, and ROTEM sigma - offers superior portability and ease of use compared to traditional laboratory methods. Despite limited randomized evidence for these new-generation devices, VET-guided algorithms effectively reduce blood product usage without compromising patient outcomes. Future validation of clinical cut-offs will be key to optimizing transfusion management.

TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges.

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran.

Practical Coagulation Management in Liver Transplantation through Point-of-Care Analysis using the TEG 6s Global Hemostasis System in Japan.

In vitro protamine addition for coagulation assessment using TEG 6s system during cardiopulmonary bypass: a pilot study.

Efficacy of point-of-care thromboelastography 6s to evaluate platelet function in a patient with pseudothrombocytopenia undergoing cardiopulmonary bypass: a case report.

Evaluation of Thromboelastography 6s prognostication of fibrinogen supplementation in pediatric cardiac surgery.

Operability of a Resonance-Based Viscoelastic Haemostatic Analyzer in the High-Vibration Environment of Air Medical Transport.

Pediatric Thromboelastograph 6s and Laboratory Coagulation Reference Values.